BPS-001 will be a novel, complex biologic treatment for metastatic, castration resistant prostate cancer (mCRPC) in patients who have failed the currently approved therapies.
The molecular biology of cancer is highly complex. Numerous biochemical signalling pathways are involved in the processes of carcinogenesis that fuel progression of the disease. Thus, an ideal drug for cancer treatment would be pleotropic, meaning that it would be able to block several major cellular pathways that drive cancer progression rather than block a single protein like the currently approved targeted inhibitors and monoclonal antibodies.
BPS-001 contains a compliment of known protein and peptide components that demonstrate anticancer activities including eliciting anti-inflammatory properties and inhibiting angiogenesis. Data also suggests that BPS-001 increases apoptosis in malignant cells.
Because BPS-001 acts on multiple pathways of carcinogenesis, we propose that tumor cells are less likely to confer drug resistance. Furthermore, preliminary toxicology studies show no adverse effects on blood chemistries or blood counts and no changes to normal tissues.
BPS-001 has demonstrated, in the pre-clinical setting, the potential to target prostate cancer at all stages. Success in the planned phase 1/2 clinical trial will position BPS-001 to emerge as a viable and alternate treatment option.